Toward a new concept of “natural balance” in oral estroprogestin contraception

References

• Cibula D. Women’s contraceptive practices and sexual behaviour in Europe. Eur J Contracept Reprod Health Care 2008;13:362–75
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M. Contraception today. Ann N Y Acad Sci 2006;1092:1–32
   PubMed Web of Science ®Google Scholar
• Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004;9:57–68
   PubMed Web of Science ®Google Scholar
• Glasier A. Contraception – past and future. Nat Cell Biol 2002;4:s3–6
   Web of Science ®Google Scholar
• van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011;(11):CD003553
   Google Scholar
• Jordan AM. Pulmonary embolism. Lancet 1961;II:1146–7
   Google Scholar
• Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;1:1097–101
   PubMed Web of Science ®Google Scholar
• Drife J. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients? Drug Saf 2002;25:893–902
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009:339:b2890
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575–82
   PubMed Web of Science ®Google Scholar
• Batur P, Elder J, Mayer M. Update on contraception: benefits and risks of the new formulations. Cleve Clin J Med 2003;70:668–90
   Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257–66
   PubMed Web of Science ®Google Scholar
• Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care 2010;15:S12–18
   PubMed Web of Science ®Google Scholar
• Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during post-menopausal replacement therapy. N Engl J Med 1981;304:560–3
   PubMed Web of Science ®Google Scholar
• Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011;183:E1319–25
   PubMed Web of Science ®Google Scholar
• Jamin C. [How to classify hormonal contraceptives?]. J Gynecol Obstet Biol Reprod (Paris) 2012;41:103–4. [French]
   PubMedGoogle Scholar
• Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012;91:769–78
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589–93
   PubMed Web of Science ®Google Scholar
• Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593–6
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83–8
   PubMed Web of Science ®Google Scholar
• Farmer RDT, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83–8
   PubMed Web of Science ®Google Scholar
• Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151
   PubMed Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131–9
   PubMed Web of Science ®Google Scholar
• Position statement: CPMP concludes its assessment of ‘third generation’ combined oral contraceptives and the risk of venous thromboembolism. London: Committe for Proprietary Medicinal Products. Eur Med Agency, 2001. Report No.: EMEA/CPMP/2250/01/en/Final
   Google Scholar
• Pharmacovigilance working party. May 2011 plenary meeting. EMA/CHMP/PhVWP/394737/2011
   Google Scholar
• Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res 2011;127:S30–4
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Grimes DA. Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives. Contraception 2008;78:201–3
   PubMed Web of Science ®Google Scholar
• Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169:610–5
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151–7
   PubMed Web of Science ®Google Scholar
• Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010;126:5–11
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturita 2008;61:171-80
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004;70:97–106
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169–78
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Plu-Bureau G, Menard J, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007;92:2074–9
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482–90
   PubMed Web of Science ®Google Scholar
• Sandset PM, Høibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res 2009;123:S70–3
   Web of Science ®Google Scholar
• Guideline on clinical investigation of steroid contraceptives in women. London: European Medicines Agency. Committee for Medicinal Products for Human Use. EMEA/CPMP/EWP/519/98 Rev 1
   Google Scholar
• Guengerich FP. Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990;47:1981–8
   PubMed Web of Science ®Google Scholar
• Coelingh Benninck HJT. Are all estrogens the same? Maturitas 2008;61:195–201
   PubMed Web of Science ®Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511–8
   PubMed Web of Science ®Google Scholar
• Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 1994;170:1499–507
   PubMed Web of Science ®Google Scholar
• Calaf I, Alsina J. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:S9–11
   Web of Science ®Google Scholar
• Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:2297–300
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012;344:e2990
   PubMed Web of Science ®Google Scholar
• Sidney S, Cheetam TC, Connel FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013;87:93–100
   PubMed Web of Science ®Google Scholar
• Dinger JC, Pineda AA. Risk of VTE in users of an etonogestrel containing vaginal ring and combined oral contraceptives (abstract presented at the 61st Annual ACOG meeting, 2012)
   Google Scholar
• van Vliet HA, Frolich M, Christella M, et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005;20:563–8
   PubMed Web of Science ®Google Scholar
• Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 2000;27:113–24
   PubMedGoogle Scholar
• Astedt B, Svanberg L, Jeppsson S, et al. The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives. Br Med J 1977;1:269
   PubMed Web of Science ®Google Scholar
• Astedt B, Jeppsson S, Liedholm P, et al. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol. Br J Obstet Gynaecol 1979;86:732–6
   PubMedGoogle Scholar
• Serup J, Bostofte E, Larsen S, et al. Natural oestrogens for oral contraception. Lancet 1979;2:471–2
   PubMed Web of Science ®Google Scholar
• Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand 1987;66:543–7
   PubMed Web of Science ®Google Scholar
• Wenzl R, Bennink HC, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993;60:616–9
   PubMed Web of Science ®Google Scholar
• Kivinen S, Saure A. Efficacy and tolerability of a combined oral contraceptive containing 17 betaestradiol and desogestrel. Eur J Contracept Reprod Health Care 1996;1:183
   Google Scholar
• Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception 1996;54:333–8
   PubMed Web of Science ®Google Scholar
• Szarewski A, Mansour D, Shulman LP. 50 years of “The Pill”: celebrating a golden anniversary. J Fam Plann Reprod Health Care 2010; 36:231–8
   PubMed Web of Science ®Google Scholar
• Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011;31:573–84
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Parke S, et al. Hemostatic effects of a novel estradiol-based oral contraceptive. Drugs R D 2011;11:159–70
   PubMedGoogle Scholar
• Lidegaard Ø. Thromboembolic complications in users of estradiolvalerate/dienogest oral contraceptives. First global conference in contraception, reproductive and sexual health Copenhagen, May 24, 2013. [Internet]. [Cited 2013 June 11]. Available from: http://www.lidegaard.dk/Slides/OC%20epidem/PP-VTE%2013-05-23%20Qlaira.pdf
   Google Scholar
• Bitzer J, Simon JA. Current issues and available options in combined hormonal contraception. Contraception 2011;84:342–56
   PubMed Web of Science ®Google Scholar
• Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19 norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239–46
   PubMed Web of Science ®Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188–215
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Bühling KJ. Why use of dienogest for the first contraceptive pill with estradiol? Gynecol Endocrinol 2010;26:109–13
   PubMed Web of Science ®Google Scholar
• Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 2010;70:541–59
   PubMed Web of Science ®Google Scholar
• Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531–9
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Chassard D, Ochsenbein E, et al. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-estradiol: a double-blind, randomised, dose-finding study. Eur J Contracept Reprod Health Care 2011;16:76–84
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Serfaty D, Chabbert-BUFFET N, et al. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod 2011;26:1338–47
   PubMed Web of Science ®Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011;16:430–43
   PubMed Web of Science ®Google Scholar
• Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444–57
   PubMed Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560–7
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care 2010;15:314–25
   PubMed Web of Science ®Google Scholar
• Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117:33–40
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology [Internet]. [Cited 2013 April 25]. Available from: http://www.whocc.no/atc_ddd_index/?code=G03AA14
   Google Scholar